[{"id":"c6f9cbc2-76fa-4211-9fb0-5b14aa0568d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04020575","created_at":"2021-01-18T19:44:34.590Z","updated_at":"2024-07-02T16:35:45.435Z","phase":"Phase 1","brief_title":"Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)","source_id_and_acronym":"NCT04020575","lead_sponsor":"Minerva Biotechnologies Corporation","biomarkers":" HER-2 • PGR • MUC1","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR negative • ER negative • MUC1 expression • HR positive + HER-2 negative","tags":["HER-2 • PGR • MUC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR negative • ER negative • MUC1 expression • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e huMNC2-CAR22 • huMNC2-CAR44 CAR T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 69","initiation":"Initiation: 01/15/2020","start_date":" 01/15/2020","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/15/2035","study_completion_date":" 01/15/2035","last_update_posted":"2023-06-16"},{"id":"d00b2e3d-6daa-4a73-8c4b-593bd302aca4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05812326","created_at":"2023-04-13T14:03:25.696Z","updated_at":"2024-07-02T16:35:50.658Z","phase":"Phase 1/2","brief_title":"PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer","source_id_and_acronym":"NCT05812326","lead_sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","biomarkers":" PD-1","pipe":" | ","alterations":" MUC1 expression","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC1 expression"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 05/17/2019","start_date":" 05/17/2019","primary_txt":" Primary completion: 11/16/2022","primary_completion_date":" 11/16/2022","study_txt":" Completion: 11/16/2022","study_completion_date":" 11/16/2022","last_update_posted":"2023-04-13"},{"id":"0e2c53e2-5daa-4613-9cf4-4a3a1038b338","acronym":"","url":"https://clinicaltrials.gov/study/NCT03198052","created_at":"2021-01-18T15:46:10.109Z","updated_at":"2024-07-02T16:35:55.664Z","phase":"Phase 1","brief_title":"GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers","source_id_and_acronym":"NCT03198052","lead_sponsor":"Second Affiliated Hospital of Guangzhou Medical University","biomarkers":" EGFR • HER-2 • CLDN18 • AXL • MSLN • MUC1 • CD276 • GPC3 • GUCY2C • PSCA","pipe":" | ","alterations":" MSLN expression • EGFR positive • GPC3 expression","tags":["EGFR • HER-2 • CLDN18 • AXL • MSLN • MUC1 • CD276 • GPC3 • GUCY2C • PSCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • EGFR positive • GPC3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/01/2017","start_date":" 07/01/2017","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2023-02-14"},{"id":"c1bed97e-11d6-4bc0-9436-ed6e5ea85e30","acronym":"","url":"https://clinicaltrials.gov/study/NCT03222674","created_at":"2021-01-18T15:54:20.717Z","updated_at":"2024-07-02T16:37:06.013Z","phase":"Phase 1/2","brief_title":"Multi-CAR T Cell Therapy for Acute Myeloid Leukemia","source_id_and_acronym":"NCT03222674","lead_sponsor":"Shenzhen Geno-Immune Medical Institute","biomarkers":" CD38 • CD33 • NCAM1 • IL3RA","pipe":"","alterations":" ","tags":["CD38 • CD33 • NCAM1 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells"],"overall_status":"Unknown status","enrollment":" Enrollment 10","initiation":"Initiation: 07/15/2017","start_date":" 07/15/2017","primary_txt":" Primary completion: 12/31/2019","primary_completion_date":" 12/31/2019","study_txt":" Completion: 12/31/2020","study_completion_date":" 12/31/2020","last_update_posted":"2018-10-17"},{"id":"d9ca2d5a-9151-4957-8ac9-e89e48ab0b87","acronym":"","url":"https://clinicaltrials.gov/study/NCT03706326","created_at":"2021-01-18T18:09:39.373Z","updated_at":"2024-07-02T16:37:06.033Z","phase":"Phase 1/2","brief_title":"CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer","source_id_and_acronym":"NCT03706326","lead_sponsor":"The First Affiliated Hospital of Guangdong Pharmaceutical University","biomarkers":" PD-1","pipe":" | ","alterations":" MUC1 expression","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anti-MUC1 CAR-T cells"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 09/28/2018","start_date":" 09/28/2018","primary_txt":" Primary completion: 09/28/2021","primary_completion_date":" 09/28/2021","study_txt":" Completion: 09/28/2021","study_completion_date":" 09/28/2021","last_update_posted":"2018-10-16"},{"id":"e9a7e7b6-1a5e-486e-8b08-7dd3db167ff3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03525782","created_at":"2021-01-17T17:27:01.690Z","updated_at":"2024-07-02T16:37:10.716Z","phase":"Phase 1/2","brief_title":"Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC","source_id_and_acronym":"NCT03525782","lead_sponsor":"The First Affiliated Hospital of Guangdong Pharmaceutical University","biomarkers":" PD-1","pipe":" | ","alterations":" MUC1 expression","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • anti-MUC1 CAR-T cells"],"overall_status":"Unknown status","enrollment":" Enrollment 60","initiation":"Initiation: 02/01/2018","start_date":" 02/01/2018","primary_txt":" Primary completion: 01/31/2021","primary_completion_date":" 01/31/2021","study_txt":" Completion: 01/31/2022","study_completion_date":" 01/31/2022","last_update_posted":"2018-05-16"},{"id":"d5f1c7b7-571c-4dca-be3f-7ecc50e0892d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03179007","created_at":"2021-01-18T15:40:32.243Z","updated_at":"2024-07-02T16:37:21.339Z","phase":"Phase 1/2","brief_title":"CTLA-4 and PD-1 Antibodies Expressing MUC1-CAR-T Cells for MUC1 Positive Advanced Solid Tumor","source_id_and_acronym":"NCT03179007","lead_sponsor":"Shanghai Cell Therapy Research Institute","biomarkers":" MUC1 • CTLA4","pipe":" | ","alterations":" MUC1 expression","tags":["MUC1 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Unknown status","enrollment":" Enrollment 40","initiation":"Initiation: 06/07/2017","start_date":" 06/07/2017","primary_txt":" Primary completion: 01/20/2019","primary_completion_date":" 01/20/2019","study_txt":" Completion: 04/20/2019","study_completion_date":" 04/20/2019","last_update_posted":"2017-06-07"},{"id":"6b86dd16-913f-4c78-bcba-295630147d99","acronym":"","url":"https://clinicaltrials.gov/study/NCT02587689","created_at":"2021-01-18T12:33:16.714Z","updated_at":"2024-07-02T16:37:27.283Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor","source_id_and_acronym":"NCT02587689","lead_sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","biomarkers":" HER-2 • ER • ALK • PGR","pipe":" | ","alterations":" EGFR mutation • HER-2 negative • ER negative • ALK translocation • MUC1 expression","tags":["HER-2 • ER • ALK • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 negative • ER negative • ALK translocation • MUC1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anti-MUC1 CAR-T cells"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 10/01/2015","start_date":" 10/01/2015","primary_txt":" Primary completion: 10/01/2017","primary_completion_date":" 10/01/2017","study_txt":" Completion: 10/01/2018","study_completion_date":" 10/01/2018","last_update_posted":"2016-12-05"}]